Merlin Biotech reports $50,000 debt offering to SEC
The Doylestown, Pennsylvania biotech's Form D shows a small debt raise sold to two investors, signed August 11, 2026.
Merlin Biotech, Inc. filed a Form D notice with the SEC disclosing a securities offering. The Delaware corporation was formed in 2022 and lists its name as Merlin Biotech, Inc.1 Its principal place of business is 3805 Old Easton Road, Doylestown, Pennsylvania.1
The offering was for debt securities1, and the company claimed the Rule 506(b) exemption under Regulation D.1 The total offering amount and the total amount sold were both listed as $50,000, with $0 remaining to be sold.1 The filing shows two investors have already put money into the offering.1 The minimum investment accepted from any outside investor was listed as $0.1
The filing marks the date of first sale as June 30, 2026.1 The company said it does not intend the offering to last more than one year.1 The offering was not made in connection with a business combination transaction such as a merger or acquisition.1
No sales commissions, finder's fees, or payments to executives, directors, or promoters from the offering proceeds were reported. Sales commissions, finders' fees, and use of proceeds to insiders were each listed at $0.1
Related persons named in the filing include Randall Hyer as an executive officer and director, along with Carol Brosgart, Jay Bhatia, and Loren Danzis as directors, and Nikhil Heble and Nick Spring as executive officers.1 Randall Hyer signed the filing as CEO on August 11, 2026.1 The company operates in the biotechnology sector.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.